abc

Abacavir sulfate (Ziagen) , a nucleoside analogue, effectively utilize its antiviral activity

ABC99 is a selective irreversible inhibitor of the wnt-deacylating enzyme. ABC99 inhibited NOTUM (IC50: 13 nM). It also showed excellent selectivity across the serine hydrolase family.

ABC1183 is a novel diaminothiazole that inhibits GSK3α, GSK3β and CDK9. ABC1183 inhibits the growth of a numerous cancer cell lines by decreasing cell survival by inducing G2 M arrest and through altering GSK3, glycogen synthetase, β-catenin phosphorylation and MCL1 expression,and is orally active.

ABC294735 is a dual SK1/SK2 inhibitor with potential anticancer activity.

ABC34 is an inactive control probe for JJH260 , the inhibitor of androgen-induced gene 1 (AIG1), an enzyme that hydrolyzes fatty acid esters of hydroxy fatty acids (FAHFAs). ABC34 demonstrates an IC50 value greater than 25 μM for the inhibition of 9-PAHSA but is more potent in blocking the serine hydrolase ABHD6 and the palmitoyl-protein hydrolase PPT1, which are both off-targets of JJH260.

ABC44 is a potent inhibitor of serine hydrolase with IC50s of 0.1 μM and 6.5 μM for palmitoyl protein thioesterase 1 (PPT1) in situ and in vitro, respectively. ABC44 can be used to study late infantile neuron-like lipofuscinosis.

Sabcomeline HCl is an M1 receptor agonist that can be used to study Alzheimer's disease.

(Rac)-Sabcomeline ((Rac)-SB-202026) is an M1/M4 muscarinic agonist used in the study of neurologic disorders such as schizophrenia.

Nestifylline is a biochemical.

Ulviprubart, an anti-KLRG1 monoclonal antibody (mAb), is utilized in various disease research [1].

Lanatoside is an FDA-approved cardiac glycoside that has been identified as a candidate anti-dengue compound. It has also been found to promote atherosclerosis. It also has anti-tumor activity, inhibiting the growth of colorectal cancer cells and liver cancer cells.

Opaganib (ABC294640) is an orally active and specific sphingosine kinase-2 (SphK2) inhibitor (IC50: 60 μM).

MC-Val-Cit-PABC-PNP, also known as Mc-Val-Cit-PABC-PNP, is a cathepsin cleavable ADC peptide linker. For example, FDA approved drug, brentuximab vedotin, adopts this linker. Protein- and peptide-drug conjugates hold a promising stance in the delivery of therapeutic agents by providing distinct advantage of improving therapeutic potential of drugs. Use of specialized linkers makes them unique in their in vivo therapeutic application by providing target tissue-specific release of drug.

Mepazine (Pecazine) is a potent and selective inhibitor of MALT1, inhibiting GSTMALT1 full length and GSTMALT1 325-760 with IC50s of 0.83 μM and 0.42 μM, respectively. Mepazine enhances apoptosis and impacts cell viability.

MAC-VC-PABC-ST7612AA1 is a part of antibody drug conjugates (ADCs) charged with HDAC inhibitor by a linker, shows antitumor activity[1].

ABCG2-IN-2 is a potent inhibitor of ABCG2, showing favorable oral pharmacokinetic profiles in mice, and is applicable for investigating tumor multidrug resistance (MDR) and erythropoietic protoporphyria (EPP) [1].

Val-Ala-PABC-Exatecan trifluoroacetate is a drug-linker conjugate for antibody-drug conjugates (ADC), comprising a cleavable Tesirine linker, Val-Ala-PABC, and the topoisomerase I inhibitor Exatecan. This compound facilitates the synthesis of ADC molecules, including Mal-PEGn-amide-va-Exatecan [1].

Mal-PEG1-Val-Cit-PABC-OH is a 1-unit polyethylene glycol (PEG) ADC linker with cleavable properties, used in the synthesis of antibody-drug conjugates (ADCs) to facilitate drug-antibody conjugation[1].

Dabcyl-KTSAVLQSGFRKME-Edans TFA, a fluorogenic peptide, serves as a substrate for quantifying protease enzymatic activities. This compound is also under investigation for its applicability in studying 2019-nCoV (COVID-19) infection [1] [2] [3].

MC-VC-PABC-Aur0101 is a potent anticancer drug-linker conjugate for Antibody-Drug Conjugates (ADCs), incorporating Aur0101, an auristatin microtubule inhibitor, linked via the MC-VC-PABC linker to boost antitumor efficacy.

Sabcomeline, a potent and functionally selective partial agonist at muscarinic M1 receptors, enhances cognition and is utilized in Alzheimer's disease research [1] [2].

AcLys-PABC-VC-Aur0101 is a drug-linker conjugate for anti-CXCR4 ADC, exhibiting potent antitumor activity and comprising the auristatin microtubule inhibitor Aur0101, connected through the cleavable linker AcLys-PABC-VC[1].

ABCB1-IN-1 (compound 3) is a potent ABCB1 inhibitor that promotes cell apoptosis, featuring 1-benzylimidazole and exhibiting IC50 values of 1.26 μM for Colo205 cells and 2.21 μM for Colo320 cells, respectively [1].

MC-VC-PABC-C6-alpha-Amanitin is an antibody-drug conjugate that combines the anticancer toxin alpha-Amanitin with the monoclonal antibody MC-VC-PABC-C6. Alpha-Amanitin, a potent inhibitor of RNA polymerase IIα, enables the conjugate to selectively target and recognize HER2-positive tumor cells, making it a valuable research tool in the study of breast and gastric cancers [1].

DBCO-Val-Cit-PABC-OH, a cleavable linker, is used in the synthesis of antibody-drug conjugates (ADCs) [1].

vc-PABC-DM1 is a chemical compound utilized for the synthesis of an antibody-drug conjugate (ADC) that incorporates a disulfide linker. This compound is instrumental in investigating serum stability [1].

TCO-PEG1-Val-Cit-PABC-OH, a cleavable 1-unit PEG ADC linker, is employed in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-VC-PABC-amide-PEG1-CH2-CC-885 is an Antibody-Drug Conjugate (ADC) that employs a protein-degrading agent (protac molecular glue, etc.).

Val-Ala-PABC-Exatecan is a Drug-Linker Conjugate for Antibody-Drug Conjugate (ADC) synthesis, comprising a cleavable Tesirine linker (Val-Ala-PABC) and the topoisomerase I inhibitor Exatecan. It is used in the construction of ADC molecules, including Mal-PEGn-amide-va-Exatecan [1].

MC-VA-PABC-MMAE is a conjugate composed of the ADC linker peptide MC-VA-PABC and the cytotoxic agent monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization [1] [2]. It functions as an agent-linker module for antibody-drug conjugates (ADCs).

MTvkPABC-P5d, functioning as a TLR7 agonist, serves as an immune stimulant and is utilized in the synthesis of immune-stimulating antibody conjugates (ISACs) [1].

Sabcomeline is a selective M1 receptor partial agonist.

DBCO-Val-Cit-PABC-PNP is a cleavable linker used in the synthesis of antibody-drug conjugates (ADC) [1].

Mal-PEG8-Val-Ala-PABC is a cleavable linker used in the synthesis of Tesirine, an agent-linker conjugate for Antibody-Drug Conjugates (ADC) [1].

N3-PEG8-Phe-Lys-PABC-Gefitinib is an antibody-drug conjugate (ADC) agent-linker complex exhibiting potent antitumor activity. It incorporates the orally active EGFR tyrosine kinase inhibitor Gefitinib, tethered by the cleavable linker N3-PEG8-Phe-Lys-PABC. As a click chemistry reagent, it features an azide group facilitating copper-catalyzed azide-alkyne cycloaddition (CuAAC) with alkyne-bearing molecules. Additionally, it can engage in strain-promoted alkyne-azide cycloaddition (SPAAC) with compounds presenting DBCO or BCN groups.

Ac-Lys-Val-Cit-PABC-MMAE is a conjugate consisting of an antibody-drug conjugate (ADC) linker (peptide Ac-Lys-Val-Cit-PABC) and the cytotoxic agent monomethyl auristatin E (MMAE), a potent tubulin polymerization inhibitor [1].

Ac-Lys-Val-Cit-PABC-MMAE (formic) is an agent-linker conjugate used in antibody-drug conjugates (ADCs), consisting of a peptide linker (Ac-Lys-Val-Cit-PABC) attached to the cytotoxic agent Monomethyl auristatin E (MMAE), a potent inhibitor of tubulin polymerization[1].

ABCG2-IN-1 (compound K2), an analog of Ko143, is an orally active inhibitor of ABCG2 with an IC50 of 0.13 μM, demonstrating favorable oral pharmacokinetics in mice and showing promise for further research [1].

'(Ac)Phe-Lys(Alloc)-PABC-PNP serves as a valuable cleavable linker in the development of antibody-drug conjugates.'

BCN-PEG1-Val-Cit-PABC-OH is a cleavable 1-unit PEG linker used in the synthesis of antibody-drug conjugates (ADCs)[1].

MC-VC-PABC-SP 141 is a potent antitumor conjugate for antibody-drug conjugation (ADC), featuring SP 141, a robust MDM2 inhibitor, connected through the cleavable linker [MC-VC-PABC], facilitating targeted cancer therapy.

Dabcyl YVADAPV EDANS is a fluorescent IL-1β converting enzyme (ICE) substrate that can be used to detect ICE-like protease activity. Dabcyl YVADAPV EDANS detects fluorescence at λex=360 nm, λem=480 nm.

AcLysValCit-PABC-DMAE-SW-163D is a drug-linker conjugate for antibody-drug conjugates (ADCs), incorporating the natural bis-intercalator SW-163D through an AcLysValCit-PABC-DMAE linker[1].